Top

American Journal of Cardiovascular Drugs

Published in:

15-05-2023 | Coronary Heart Disease | Review Article

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction

Authors: Jessica Huston, Hannah Schaffner, Alyssa Cox, Alexander Sperry, Shelby Mcgee, Payeng Lor, Logan Langley, Blake Skrable, Majdi Ashchi, Mohannad Bisharat, Ashwini Gore, Thomas Jones, David Sutton, Mae Sheikh-Ali, Jason Berner, Rebecca Goldfaden

Published in: American Journal of Cardiovascular Drugs | Issue 4/2023

Abstract

Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in adults. IPE is an esterified version of eicosapentaenoic acid (EPA) and acts as a prodrug in the body to exert its effects. IPE affects the body primarily through triglyceride (TG) reduction and was initially indicated for hypertriglyceridemia in addition to statin therapy or for patients with statin intolerances. Various studies have investigated this agent, and multiple subanalyses have been conducted since the FDA approval. These subanalyses have assessed factors such as sex, statin therapy, high-sensitivity C-reactive protein levels (hs-CRP), and various inflammatory biomarkers in groups of patients taking IPE. This article aims to provide a critical review of the clinical data available regarding cardiovascular benefits of IPE in patients with ASCVD and its value as a treatment option for patients with elevated TG levels.

World Health Organization. (n.d.). The top 10 causes of death. World Health Organization. Retrieved June 30, 2022, from https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 30 Jun 2022.

Centers for Disease Control and Prevention. Heart disease facts. Centers for Disease Control and Prevention. 2022. Retrieved June 30, 2022, from https://www.cdc.gov/heartdisease/facts.htm. Accessed 30 Jun 2022.

Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330–43. https://doi.org/10.1016/j.jacc.2018.04.061.CrossRefPubMed

Wong ND, Zhao Y, Quek R, Blumenthal RS, Budoff MJ, Cushman M, Garg P, Sandfort V, Tsai M, Lopez J. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol. 2017;11(5):1223–33. https://doi.org/10.1016/j.jacl.2017.06.015.CrossRefPubMedPubMedCentral

Daniels SR. Guidelines for Screening, Prevention, Diagnosis and Treatment of Dyslipidemia in Children and Adolescents. [Updated 2020 Jan 18]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395579/?report. Accessed 30 Jun 2022.

Update on phase III strength trial for epanova in mixed ... - astrazeneca. (n.d.). Retrieved June 30, 2022, from https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html. Accessed 30 Jun 2022.

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet (London, England). 2007;369(9567):1090–8. https://doi.org/10.1016/S0140-6736(07)60527-3.CrossRefPubMed

Budoff MJ, Muhlestein JB, Bhatt DL, Le Pa VT, May HT, Shaikh K, Shekar C, Kinninger A, Lakshmanan S, Roy SK, Tayek J, Nelson JR. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovasc Res. 2021;117(4):1070–7. https://doi.org/10.1093/cvr/cvaa184.CrossRefPubMed

About VASCEPA® (icosapent Ethyl). (n.d.). Official Patient Site | VASCEPA® (icosapent ethyl). https://www.vascepa.com/about-vascepa/(n.d.). Amarin Corporation. https://amarincorp.com/docs/Vascepa-PI.pdf. Accessed 30 Jun 2022.

10.

Weintraub WS, Bhatt DL, Zhang Z, et al. Cost-effectiveness of icosapent ethyl for high-risk patients with hypertriglyceridemia despite statin treatment. JAMA Netw Open. 2022;5(2):e2148172. https://doi.org/10.1001/jamanetworkopen.2021.48172.CrossRefPubMedPubMedCentral

11.

Nelson JR, Raskin S. The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgrad Med. 2019;131(4):268–77. https://doi.org/10.1080/00325481.2019.1607414.CrossRefPubMed

12.

Brinton EA, Mason RP. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids Health Dis. 2017;16:23. https://doi.org/10.1186/s12944-017-0415-8.CrossRefPubMedPubMedCentral

13.

Yang ZH, Amar M, Sampson M, et al. Comparison of omega-3 eicosapentaenoic acid versus docosahexaenoic acid-rich fish oil supplementation on plasma lipids and lipoproteins in normolipidemic adults. Nutrients. 2020;12(3):749. https://doi.org/10.3390/nu12030749.CrossRefPubMedPubMedCentral

14.

Sherratt SCR, Libby P, Bhatt DL, et al. A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot Essent Fatty Acids. 2022;182:102450. https://doi.org/10.1016/j.plefa.2022.102450.CrossRefPubMed

15.

Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126(7):7–18. https://doi.org/10.3810/pgm.2014.11.2828.CrossRefPubMed

16.

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol. 2011;108(5):682–90. https://doi.org/10.1016/j.amjcard.2011.04.015.CrossRefPubMed

17.

Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR Study). Am J Cardiol. 2012;110(7):984–92. https://doi.org/10.1016/j.amjcard.2012.05.031.CrossRefPubMed

18.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, REDUCE-IT Investigators, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. Circulation. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRef

19.

Gaba P, Bhatt DL, Steg PG, REDUCE‐IT Investigators, et al. Prevention of cardiovascular events and mortality with icosapent ethyl in patients with prior myocardial infarction. J Am Coll Cardiol. 2022;79(17):1660–71. https://doi.org/10.1016/j.jacc.2022.02.035.CrossRefPubMed

20.

Gaba P, Bhatt DL, Mason RP, REDUCE‐IT Investigators, et al. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: a review of key findings from REDUCE-IT. J Clin Lipidol. 2022. https://doi.org/10.1016/j.jacl.2022.05.067.CrossRefPubMed

21.

Bhatt DL, Miller M, Brinton EA, et al. REDUCE-IT USA. Circulation. 2020;141(5):367–75. https://doi.org/10.1161/CIRCULATIONAHA.119.044440.CrossRefPubMed

22.

Gaba P, Bhatt DL, Giugliano RP, et al. Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT. J Am Coll Cardiol. 2021;78(15):1525–37. https://doi.org/10.1016/j.jacc.2021.08.009.CrossRefPubMed

23.

Verma S, Bhatt DL, Steg PhG, et al. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144(23):1845–55. https://doi.org/10.1161/CIRCULATIONAHA.121.056290.CrossRefPubMed

24.

Jithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144(22):1750–9. https://doi.org/10.1161/CIRCULATIONAHA.121.055560.CrossRef

25.

Singh N, Bhatt DL, Miller M, et al. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am Coll Cardiol. 2022;79(2):220–2. https://doi.org/10.1016/j.jacc.2021.11.005.CrossRefPubMed

26.

Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT Biomarker Substudy. Circulation. 2022. https://doi.org/10.1161/CIRCULATIONAHA.122.059410.CrossRefPubMed

27.

Selvaraj S, Bhatt DL, Steg PG, et al. Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT. J Am Heart Assoc. 2022;11(7):e024999. https://doi.org/10.1161/JAHA.121.024999.CrossRefPubMedPubMedCentral

28.

Peterson BE, Bhatt DL, Steg PG, REDUCE‐IT Investigators, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention: insights from REDUCE-IT PCI. J Am Heart Assoc. 2022;11(6):e022937. https://doi.org/10.1161/JAHA.121.022937.CrossRefPubMedPubMedCentral

29.

Miller M, Bhatt DL, Steg PG, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking [published online ahead of print, 2022 Aug 11]. Eur Heart J Cardiovasc Pharmacother. 2022. https://doi.org/10.1093/ehjcvp/pvac045.CrossRefPubMedCentral

30.

Daida H. Randomized trial for evaluation in secondary prevention efficacy of combination therapy–statin and eicosapentaenoic acid—RESPECT-EPA. In: Presented at: the American Heart Association Scientific Sessions, Chicago, IL, November 6, 2022.

31.

Nishizaki Y, Miyauchi K, Iwata H, et al. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2023;257:1–8. https://doi.org/10.1016/j.ahj.2022.11.008.CrossRefPubMed

32.

Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70(6):537–44. https://doi.org/10.1016/j.jjcc.2017.07.007.CrossRefPubMed

33.

Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925–32. https://doi.org/10.1093/eurheartj/ehaa652.CrossRefPubMedPubMedCentral

34.

Bryn Mawr Communications. Amarin's VAZKEPA recommended in UK nice final draft guidance for prevention of cardiovascular events in patients with raised triglycerides. Cardiac Interventions Today. Retrieved July 15, 2022, from https://citoday.com/news/amarins-vazkepa-recommended-in-uk-nice-final-draft-guidance-for-prevention-of-cardiovascular-events-in-patients-with-raised-triglycerides-1#:~:text=June%2010%2C%202022%E2%80%94The%20United,in%20adults%20who%20have%20raised. Accessed 15 Jul 2022.

35.

Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. Curr Opin Cardiol. 2019;34(6):721–7. https://doi.org/10.1097/HCO.0000000000000678.CrossRefPubMed

36.

Alfaddagh A, Kapoor K, Dardari ZA, et al. Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: implications for primary prevention. Atherosclerosis. 2022;353:11–9. https://doi.org/10.1016/j.atherosclerosis.2022.06.1018.CrossRefPubMed

37.

Nissen SE, Lincoff AM, Wolski K, et al. Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH Trial. JAMA cardiology. 2021. https://doi.org/10.1001/jamacardio.2021.1157.CrossRefPubMedPubMedCentral

38.

Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(Supplement_J):J34–48. https://doi.org/10.1093/eurheartj/suaa117.CrossRefPubMedPubMedCentral

39.

Ambrosy AP, Malik UI, Thomas RC, et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021;235:54–64. https://doi.org/10.1016/j.ahj.2021.01.018.CrossRefPubMedPubMedCentral

40.

A pragmatic randomized trial of icosapent ethyl for high-cardiovascular risk adults - full text view. A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults - Full Text View - ClinicalTrials.gov. (n.d.). Retrieved July 15, 2022, from https://clinicaltrials.gov/ct2/show/NCT04505098.

41.

Derington CG, Bress AP, Herrick JS, et al. The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. Am J Prev Cardiol. 2022;10:100345. https://doi.org/10.1016/j.ajpc.2022.100345.CrossRefPubMedPubMedCentral

Title: A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
Authors: Jessica Huston
Hannah Schaffner
Alyssa Cox
Alexander Sperry
Shelby Mcgee
Payeng Lor
Logan Langley
Blake Skrable
Majdi Ashchi
Mohannad Bisharat
Ashwini Gore
Thomas Jones
David Sutton
Mae Sheikh-Ali
Jason Berner
Rebecca Goldfaden
Publication date: 15-05-2023
Publisher: Springer International Publishing
Keywords: Coronary Heart Disease
Nutritional Supplements and Skin
Cardiovascular Disease in General Practice
Cardiology
Nutrition
Published in: American Journal of Cardiovascular Drugs / Issue 4/2023
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-023-00583-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2023

The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Safety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome

Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

The Single-Syringe Versus the Double-Syringe Techniques of Adenosine Administration for Supraventricular Tachycardia: A Systematic Review and Meta-Analysis

A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia